<DOC>
	<DOCNO>NCT02508623</DOCNO>
	<brief_summary>The purpose study ass whether add Rifaximin patient liver cirrhosis esophageal varix treat standard therapy beta blocker , lead significant reduction portal hypertension .</brief_summary>
	<brief_title>Effect Administration Rifaximin Portal Pressure Patients With Liver Cirrhosis Esophageal Varices</brief_title>
	<detailed_description>It well recognize gut flora may play important role development complication liver cirrhosis , hepatic encephalopathy ( HE ) , spontaneous bacterial peritonitis ( SBP ) variceal bleeding , directly cause aggravate translocation enteric bacteria product blood cirrhotic patients.Preliminary study show selective intestinal decontamination appear ameliorate hyperdynamic circulatory state cirrhosis . The investigator hypothesize modulation gut microbiota administer non-adsorbable antibiotic , addition beta-blockers , safe strategy reduce portal pressure , influence favorably hemodynamics portal circulation . Thus , purpose study evaluate patient liver cirrhosis esophageal varix high risk bleeding , Rifaximin , administer addition standard therapy beta - blocker ( propranolol ) , time 60 day : lead significant reduction Hepatic Venous Pressure Gradient ( assess hepatic vein catheterization ) , 2 ) modify intestinal flora favor specific family bacteria ( assessed fecal microbiota analysis ) , 3 ) change systemic inflammatory response ( assessed serum pro-inflammatory cytokine ) 4 ) change cognitive function ( assessed neuropsychological electroencephalogram evaluation ) .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Hypertension , Portal</mesh_term>
	<mesh_term>Esophageal Gastric Varices</mesh_term>
	<mesh_term>Rifaximin</mesh_term>
	<mesh_term>Rifamycins</mesh_term>
	<criteria>Diagnosis liver cirrhosis ( base clinical , biochemical radiological criterion without liver biopsy ) Presence esophageal varix high risk bleed Hepatic Venous Pressure Gradient &gt; 12 mmHg . 19≤ age ≤75 Informed Consent Patients already treat beta blocker Treatment systemic antibiotic and/or nonabsorbable intestinal antibiotic previous two week Bacterial infection , spontaneous bacterial peritonitis overt hepatic encephalopathy last week active gastrointestinal bleeding , last week active alcoholism drug abuse last 3 week Acute Alcoholic Hepatitis Hepatocellular carcinoma neoplasm significant coronary artery disease ( angina NYHA III/IV ) , congestive heart failure ( NYHA III/IV ) , relevant cardiomyopathy , history myocardial infarct within last 12 month Contraindications administration beta blocker ; allergy Rifaximin Pregnancy breastfeed Refusal participate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Portal hypertension</keyword>
	<keyword>liver cirrhosis</keyword>
	<keyword>Rifaximin</keyword>
</DOC>